In vitro DNA strand scission and inhibition of nucleic acid synthesis in L1210 leukemia cells by a new class of DNA complexers, the anthra[1,9-cd]pyrazol-6(2H)-ones (anthrapyrazoles)
- PMID: 2413861
- DOI: 10.1016/0006-2952(85)90724-5
In vitro DNA strand scission and inhibition of nucleic acid synthesis in L1210 leukemia cells by a new class of DNA complexers, the anthra[1,9-cd]pyrazol-6(2H)-ones (anthrapyrazoles)
Abstract
CI-937 and CI-942 belong to a new class of DNA complexers, the anthra[1,9-cd]pyrazol-6(2H)-ones (anthrapyrazoles), and are being further developed as antitumor drugs based on their curative properties against murine solid tumour models. The biochemical effects of these agents were studied in L1210 leukemia in relation to other clinically used intercalators. After a 1-hr exposure, CI-937 and CI-942 reduced the cloning efficiency of L1210 cells by 50% at 3.0 X 10(-8) and 1.5 X 10(-7) M respectively. Based on an ethidium displacement assay, these drugs bound strongly to DNA, reducing the fluorescence of an ethidium-DNA complex by 50% at concentrations of 23 and 33 nM for CI-937 and CI-942 respectively. This was comparable to mitoxantrone at 15 nM, but much more potent than Amsacrine which required over 1.3 microM. A distinct property of the anthrapyrazoles was a much more potent inhibitory effect on whole cell DNA synthesis than on RNA synthesis. After L1210 cells were exposed to drug for 2 hr the concentration needed to inhibit DNA synthesis by 50% was 0.33 and 0.57 microM for CI-937 and CI-942, respectively, whereas 2.0 and 11.3 microM were required to inhibit RNA synthesis by the same extent. This was in contrast to Adriamycin and mitoxantrone which inhibited both activities equally at similar concentrations. It was apparent that the inhibition of these processes was not due to substrate depletion since intracellular ribonucleoside and deoxyribonucleoside triphosphates either remained constant or were elevated after a 2-hr exposure to 1 or 10 microM drug. A similar discriminatory effect was observed on DNA and RNA polymerase in permeabilized cells, and the inhibition of nucleic acid synthesis in this system could be reversed by exogenously added DNA. Since the high incidence of cardiotoxicity associated with the administration of anthracyclines has been related to the formation of reactive oxygen species, the ability of the anthrapyrazoles to augment superoxide dismutase sensitive oxygen consumption was observed in a rat liver microsomal system. CI-937 and CI-942 induced 5- and 10-fold less oxygen consumption than Adriamycin, producing rates of 12.4, 24.2 and 138.9 nmoles/min/mg microsomal protein, respectively, at a drug concentration of 0.5 mM.(ABSTRACT TRUNCATED AT 400 WORDS)
Similar articles
-
Biochemical pharmacology and DNA-drug interactions by Cl-958, a new antitumor intercalator derived from a series of substituted 2H-[1]benzothiopyrano[4,3,2-cd]indazoles.Mol Pharmacol. 1988 Jan;33(1):84-92. Mol Pharmacol. 1988. PMID: 2447481
-
Design, biochemical pharmacology, electrochemistry and tumour biology of anti-tumour anthrapyrazoles.Anticancer Drug Des. 1986 Apr;1(2):73-85. Anticancer Drug Des. 1986. PMID: 2453196
-
The biochemical pharmacology of CI-920, a structurally novel antibiotic with antileukemic activity.Adv Enzyme Regul. 1985;23:193-215. doi: 10.1016/0065-2571(85)90048-2. Adv Enzyme Regul. 1985. PMID: 3840949
-
Molecular and biochemical pharmacology of mitoxantrone.Cancer Treat Rev. 1983 Dec;10 Suppl B:3-11. doi: 10.1016/0305-7372(83)90016-6. Cancer Treat Rev. 1983. PMID: 6362876 Review.
-
Anti-cancer activities of 1,4-naphthoquinones: a QSAR study.Anticancer Agents Med Chem. 2006 Sep;6(5):489-99. doi: 10.2174/187152006778226512. Anticancer Agents Med Chem. 2006. PMID: 17017857 Review.
Cited by
-
Application of Multivariate Adaptive Regression Splines (MARSplines) for Predicting Antitumor Activity of Anthrapyrazole Derivatives.Int J Mol Sci. 2022 May 4;23(9):5132. doi: 10.3390/ijms23095132. Int J Mol Sci. 2022. PMID: 35563523 Free PMC article.
-
A phase II trial of piroxantrone in disseminated malignant melanoma. A Southwest Oncology Group study.Invest New Drugs. 1995;13(1):83-7. doi: 10.1007/BF02614226. Invest New Drugs. 1995. PMID: 7499114 Clinical Trial.
-
Pharmacokinetics, cerebrospinal fluid penetration, and metabolism of piroxantrone in the rhesus monkey.Invest New Drugs. 1993 Nov;11(4):255-61. doi: 10.1007/BF00874424. Invest New Drugs. 1993. PMID: 8157468
-
Phase II trial of piroxantrone for advanced or metastatic soft tissue sarcomas. A Southwest Oncology Group study.Invest New Drugs. 1993 Nov;11(4):337-41. doi: 10.1007/BF00874435. Invest New Drugs. 1993. PMID: 8157477 Clinical Trial.
-
Phase II trial of piroxantrone in advanced non-small cell carcinoma of the lung. A Southwest Oncology Group study.Invest New Drugs. 1992 Apr;10(1):29-30. doi: 10.1007/BF01275476. Invest New Drugs. 1992. PMID: 1318871 Clinical Trial. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources